Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exposure Targeted Melphalan Dosing in Multiple Myeloma
NCT04483206Phase 1Recruiting
- Sponsor
- Emory University
- Start
- May 2021
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of melphalan in multiple myeloma (MM), sponsored by Emory University. Primary endpoints: Area Under the Curve, Incidence of exposure limiting toxicity at 30 days and 1 more. Started May 2021; status: recruiting.
02
Drugs
melphalan
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04483206.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04483206.